Dr. Mehmi on Fianlimab and Cemiplimab in Patients with Poor-Risk, Advanced Melanoma
Source: OncLive, August 2023
Inderjit Mehmi, MD, discusses results from a subgroup analysis of patients with advanced melanoma and poor-risk features given fianlimab and cemiplimab in a phase 1 trial.
Inderjit Mehmi, MD, medical oncologist, The Angeles Clinic and Research Institute, discusses updated results from a subgroup analysis of patients with advanced melanoma and poor-risk features who were treated with fianlimab (REGN3767) and cemiplimab (Libtayo) in a phase 1 trial (NCT03005782).
The open-label, non-randomized, parallel-cohort assignment study enrolled patients with unresectable or metastatic melanoma to 1 of 3 expansion cohorts: the initial cohort, a confirmatory cohort, and a PD-L1–experienced cohort. Those in the first 2 expansion cohorts had not been previously exposed to anti-PD-1 therapy, while those in cohort 16 had been previously exposed to adjuvant or neoadjuvant systemic therapy, including a PD-L1 inhibitor.